
































































































IC50 of all drugs, all cell lines with annotations
Supplementary Figure 1: Annotated IC50 of all measured drugs.
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Supplementary Figure 2: (Correlation between IC50 and mutation status for RAS/P53 genes with mutation frequency
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Best IC50/mRNAseq correlation for GO transduction genes
Supplementary Figure 3: Top correlations between IC50 and mRNA expression for the 1000 most variable genes (top,
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Supplementary Figure 4: Principal Component Analysis of the 1000 most variable genes. All components up to the
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Supplementary Figure 5: Principal Component Analysis of the 5262 signal transduction genes as annotated in the
























































TAE684 IC50 vs ALK expression, R2= 0.0079 p−value= 0.82
Supplementary Figure 6: NF1 expression versus AZD6244 IC50 and ALK expression versus TAE684 IC50.
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Supplementary Figure 7: Receptors RNA expression (TPM).
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Adaptor & ERBB familly expression
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Supplementary Figure 9: Pair-plot of the principal components from the perturbation data in main Fig 2. All compo-















































Dominant loadings in principal components PC1, PC2 and PC3
Supplementary Figure 10: Main loadings in the first 3 principal components of the perturbation data PCA. Color
corresponds to the components for which the condition has the highest absolute weight.
Condition_PC1 PC1 Condition_PC2 PC2 Condition_PC3 PC3
PDGF+ALKi+IGF1i_AKT 0.309 IGF1+MEKi_MEK 0.302 IGF1+ASK1i_MEK -0.235
EGF+ALKi+IGF1i_AKT 0.271 NGF+MEKi_MEK 0.272 IGF1+PI3Ki_AKT -0.213
PDGF+ALKi+IGF1i_S6K 0.211 IGF1+ASK1i_MEK 0.258 IGF1+mTORC1i_S6K -0.210
EGF+ALKi+IGF1i_S6K 0.207 PDGF+MEKi_MEK 0.229 PDGF+ASK1i_S6K -0.209
IGF1+RAFi+PDGFi_AKT 0.196 EGF+MEKi_MEK 0.214 PDGF+mTORC1i_S6K -0.208
IGF1+mTORC1i_AKT 0.193 MEKi_MEK 0.208 NGF+mTORC1i_S6K -0.202
ALKi+IGF1i_AKT 0.187 IGF1+PI3Ki_AKT 0.145 IGF1_AKT -0.200
EGF+RAFi+PDGFi_S6K 0.182 ALKi+IGF1i_S6K 0.136 EGF+PI3Ki_S6K 0.183
IGF1+RAFi+PDGFi_S6K 0.181 EGF+ASK1i_AKT -0.118 EGF+AKTi_S6K 0.180
EGF+AKTi_S6K 0.167 IGF1+MEKi_ERK 0.117 IGF1+MEKi_AKT -0.179
Supplementary Table 1: Main loadings of the first 3 principal components of the perturbation data PCA.
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IMR32 best normal Q-Q plot




































































































CHP212 best normal Q-Q plot SKNAS best normal Q-Q plot
LAN6 best normal Q-Q plot SKNSH best normal Q-Q plot
Supplementary Figure 11: Quantile-quantile plots of the initial models using the literature topology (top, initial






























































Supplementary Figure 12: Correlation between the fitted path value from ligands to readouts and the expression of
the matching receptor or receptor family.
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All readout vs AZD6244 IC50 for MEKi perturbations,
Individual replicates of initial cell lines
Supplementary Figure 13: AZD6244 IC50 versus responses to perturbations including AZD6244. R2 and p.value















































































Supplementary Figure 14: Raw plex measurements of pAKT
S473
response to IGFR inhibition under serum, starved
or IGF1 condition. The AKT pathway is activated by IGFR in N206 even without serum and is not activated more

































































































































































Supplementary Figure 16: Differentially measured phosphopeptides in IMR32 and N206 after 4h inhibition (FDR <
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Overlapping phosphosites KEGG enrichment
Supplementary Figure 17: KEGG enrichment of unique genes corresponding to phosphopeptides differentially expressed
after MEKi, IGFRi or MEKi+IGFRi treatment in IMR32 (top), N206 (middle) or both strictly (bottom). MAPK
related terms are highlighted. Computation using the R package enrichKEGG.
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